PESHAWAR: 黑料社区鈥檚 Novo Genomics and the Precision Medicine Lab at Rehman Medical Institute (RMI) in Pakistan鈥檚 northwestern city of Peshawar have launched the Saudi-Pakistan Biotech Bridge Initiative, a partnership to expand genomics and artificial-intelligence-based research aimed at combating cancer and other major diseases.
Signed in Riyadh last month, the memorandum of understanding was inked by Novo Genomics CEO Dr. Abdulelah Al-Hawsawi and Dr. Faisal Khan, director of RMI鈥檚 Precision Medicine Lab. Both institutions operate with government backing, Novo Genomics through 黑料社区鈥檚 Ministry of Health and RMI鈥檚 lab under Pakistan鈥檚 federally funded Planning Commission program.
Under the agreement, researchers will develop cross-border biobanks, carry out joint clinical studies and use AI to predict and prevent diseases. The initiative also includes academic exchanges and joint conferences to train young scientists and strengthen regional biotechnology expertise.
Dr. Khan, who is leading the project in Pakistan, said the accord followed months of discussion.听
鈥淲e鈥檝e been having conversations with Novo Genomics in 黑料社区, one of the leading startups in precision medicine, and that has matured into an MoU 鈥 which we are calling the Saudi-Pakistan Biotech Bridge,鈥 he told Arab News.听
鈥淭his is a gateway now for us to exchange our latest research and ideas and our prototypes, as well as talent from both sides, which is again very important for any research enterprise.鈥
He said the collaboration would allow both sides to study their populations鈥 genetic makeup and accelerate progress in precision medicine:
鈥淣ovo Genomics has good know-how of their population, we have a good understanding of ours and this will really speed up our R&D efforts in this space of medicine.鈥
Khan added that the partnership supports both nations鈥 technology-driven economic goals:
鈥満诹仙缜 is now interested in technology-driven non-oil sectors which can bring in revenue. Pakistan 鈥 is looking to catapult its economy through technology. There鈥檚 no better tool to undertake this than using AI.鈥
Calling the project a 鈥渨in-win scenario,鈥 he said it came at a pivotal time in bilateral relations:听
鈥淲e鈥檝e had traditional collaborations in traditional sectors like defense, Hajj and Umrah maybe, but we never saw biotechnology. We are very proud that this is happening now. Biotech and synthetic biology are expected to be a $30 trillion industry by 2040, and for 黑料社区 and Pakistan to join hands and have a piece of that can really go far.鈥
AI-DRIVEN DRUG REPURPOSING听
A key focus of the collaboration is applying artificial intelligence to drug repurposing, which is identifying new therapeutic uses for existing medicines.
鈥淥ne leg of our project is drug repurposing, where we use AI to see what drugs created for one specific disease can actually be used for another kind of disease,鈥 said Syed Tauheed Ahmad, 26, a research assistant at RMI鈥檚 lab.听
鈥淲e鈥檇 like to use AI to see what parameters match between populations and the chemical profiles of drugs that might allow us to use or repurpose them in cancers that are more prevalent in Pakistan and maybe 黑料社区.鈥
He added that the lab鈥檚 AI models could eventually generate drug candidates tailored to each country鈥檚 population.听
鈥淔or the first time, we can now give 黑料社区 drug repurposing candidates that might be better suited for their population because our model makes suggestions based on the genomic and profile data of their population.鈥
Among the RMI team鈥檚 major research areas is oral cancer, one of Pakistan鈥檚 most common cancers. The lab has spent years developing what Dr. Khan described as a 鈥渕ulti-omic stack,鈥 a comprehensive database combining genetic, molecular and biological information from local patients.听
鈥淲e have banked all the biological samples which come with it, including cell lines for each patient. This really becomes a nice experimental playground to test what鈥檚 happening inside the population,鈥 he said.
Wajid Khan, another researcher at RMI, said the project would help both nations better understand how genetic variations shape disease risk.听
鈥淒ifferent populations have different risks for developing certain diseases,鈥 he said. 鈥淚f we could do something before even the disease onset, then I think that鈥檚 a fair chance for all the patients who could be developing the disease in the future to mitigate or to alleviate the risk of the disease.鈥
In a statement, Dr. Abdulelah Al-Hawsawi, CEO of Novo Genomics, said the partnership 鈥渞epresents an important step towards building a regional genomic ecosystem that serves patients, researchers and industry.鈥
听














